Abstract:Our results indicate that primary stent placement is a safe and effective treatment for iliac CTOs. However, major complications, including distal embolization and iliac artery rupture, remain a significant problem, and caution should therefore be exercised when performing this technique for iliac CTOs.
“…10 Kondo reported a 2-year primary patency rate of 90% for primary stenting of iliac artery CTOs. 11 Both studies do not report the numbers at risk in their Kaplan-Meier analysis, and keep in mind, these two studies examine different populations from our study, likely accounting for the differences in patency. In a similar fashion, direct comparison with aortobifemoral bypass is not valid, as our practice's aortobifemoral bypass patients are now mostly a historical cohort.…”
Section: Discussionmentioning
confidence: 89%
“…Technical success in revascularization of CTOs in contemporary series has been reported between 92% and 99%. 10,11 The technical failures in this study were all due to failed re-entry. For a portion of this study, no re-entry device was commercially available, contributing to this lower technical success rate.…”
Section: Discussionmentioning
confidence: 97%
“…2,7,10,11 Most of these series utilize intraluminal techniques to traverse the iliac obstruction, with a minority of lesions managed with SIA. In this study of iliac artery CTO managed exclusively with SIA, 34.7% of the lesions were graded TASC D. Although a technical success rate of 83.5% was seen in this study, the majority of these lesions were TASC C and D (61.4%), and all of these lesions were iliac artery CTOs.…”
This study demonstrates that SIA of iliac CTOs is feasible and can be performed safely and effectively, even in high-risk patients. Excellent patency and limb salvage rates can be achieved. In our experience, the safety and durability of SIA makes it an attractive first-line therapy for iliac artery occlusive disease.
“…10 Kondo reported a 2-year primary patency rate of 90% for primary stenting of iliac artery CTOs. 11 Both studies do not report the numbers at risk in their Kaplan-Meier analysis, and keep in mind, these two studies examine different populations from our study, likely accounting for the differences in patency. In a similar fashion, direct comparison with aortobifemoral bypass is not valid, as our practice's aortobifemoral bypass patients are now mostly a historical cohort.…”
Section: Discussionmentioning
confidence: 89%
“…Technical success in revascularization of CTOs in contemporary series has been reported between 92% and 99%. 10,11 The technical failures in this study were all due to failed re-entry. For a portion of this study, no re-entry device was commercially available, contributing to this lower technical success rate.…”
Section: Discussionmentioning
confidence: 97%
“…2,7,10,11 Most of these series utilize intraluminal techniques to traverse the iliac obstruction, with a minority of lesions managed with SIA. In this study of iliac artery CTO managed exclusively with SIA, 34.7% of the lesions were graded TASC D. Although a technical success rate of 83.5% was seen in this study, the majority of these lesions were TASC C and D (61.4%), and all of these lesions were iliac artery CTOs.…”
This study demonstrates that SIA of iliac CTOs is feasible and can be performed safely and effectively, even in high-risk patients. Excellent patency and limb salvage rates can be achieved. In our experience, the safety and durability of SIA makes it an attractive first-line therapy for iliac artery occlusive disease.
“…Iliac artery lesions were treated with primary stenting, while superficial femoral artery lesions were preferentially treated with balloon angioplasty and selective stenting. [8][9][10] Stents were placed in superficial femoral artery lesions only when residual stenosis and flow-limiting dissections were noticed after balloon angioplasty. Rigid balloon expandable stents such as Palmaz (Cordis Endovascular) and Express LD (Boston Scientific) were used for most common iliac artery lesions, and flexible self-expanding stents such as SMART (Cordis Endovascular) and Luminexx (BARD, Murray Hill, New Jersey) for most external iliac or superficial femoral artery lesions.…”
The purpose of this study was to describe the vascular surgeons' experience with an endovascular-first approach for critical limb ischemia (CLI) due to arteriosclerotic disease involving infrapopliteal vessels. From April 2006 to September 2013, 55 limbs with CLI in 45 consecutive patients who had undergone infrapopliteal percutaneous transluminal angioplasty (PTA) were evaluated. All limbs presented with ulcers or gangrenes (Rutherford 5 or 6), and were treated with infrapopliteal PTA as the initial treatment. Clinical outcomes of major adverse limb event (MALE) + perioperative death (POD), amputation-free survival (AFS), limb salvage, and survival were analyzed with the Kaplan–Meier method. Multivariable perioperative predictors of MALE + POD and AFS were identified using the stepwise Cox proportional hazards regression model. The technical success rate was 95% (52/55). Clinical success was attained in 37 of 55 limbs (67%). Freedom from MALE + POD, AFS, limb salvage, and survival were 89%, 84%, 92%, and 92% at 6 months, respectively, and 82%, 68%, 89%, and 78% at 12 months, respectively. Clinical success (HR, 0.06; 0.01–0.50; P = 0.009) was associated with freedom from MALE + POD. Rutherford 6 (HR, 3.0; 95% CI, 1.1–8.3; P < 0.004) and clinical success (HR, 0.19; 95% CI, 0.07–0.49; P < 0.0007) were associated with AFS. These results suggest that infrapopliteal PTA can be offered as a first therapeutic option for a significant proportion of patients with CLI. Vascular surgeons must embrace and validate endovascular technology if they are to remain competitive in treatment of peripheral artery disease.
“…These pioneering results have been validated by large contemporary series [5,6]. Not surprisingly, indications now have expanded from simple stenoses to include advanced disease such as complex stenosis, as well as occlusions [7-9]. With 96 percent technical success, perioperative morbidity <10 percent and 96 percent 3-year and 85 percent 5-year patency endovascular techniques are now the most common first approach to treat iliac artery disease [6,10,11].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.